However, the significance of S100P expression in our tumour panel was higher in locally advanced tumours (UICC Stages II–III), leaving the prognostic value of S100P in the earlier tumour stages to be evaluated in a larger cohort before its implementation in the clinical decision. This evidence concerns the gene S100P and neoplasm.